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S U M M A R Y
Background: Cytomegalovirus (CMV) is the most common cause of congenital virus infection. However,
the risk factors for infection in utero and for progression to a severe clinical outcome remain uncertain.
Recent studies have identiﬁed associations of speciﬁc single nucleotide polymorphisms (SNPs) in Toll-
like receptor (TLR) genes with susceptibility to infections of some viruses and with their clinical
outcome.
Methods: Genetic polymorphisms in the TLR-2, TLR-4, and TLR-9 genes were analyzed in 87 children
with congenital CMV infections by the TaqMan allelic discrimination assay. The frequencies of genotypes
in the general Japanese population were obtained from the National Center for Biotechnology
Information (NCBI) databases. Associations between the analyzed SNPs and congenital CMV infection or
disease were evaluated.
Results: The CC genotype at SNP rs3804100 in the TLR-2 gene was signiﬁcantly associated with
congenital CMV infection but not with congenital CMV disease. Furthermore, the AG genotype at SNP
rs1898830 in the TLR-2 gene tended to be identiﬁed less frequently in children with congenital CMV
infection. There were no statistically signiﬁcant associations between SNPs in the TLR-4 and TLR-9 genes
and congenital CMV infection or disease.
Conclusion: TLR-2 polymorphisms may have some association with congenital CMV infection, although
the mechanism underlying this effect remains to be clariﬁed.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human cytomegalovirus (CMV) is a leading cause of congenital
virus infections in developed countries, such as the USA, where
rubella has been eliminated and antiviral treatment is available for
HIV.1 The risk of transmission of CMV to the fetus due to primary
maternal infection during pregnancy ranges from 14% to 52%.2,3 As
many as 10–15% of infants with congenital CMV infection exhibit
severe, classic ‘cytomegalic inclusion disease’, characterized by
intrauterine growth retardation (IUGR), jaundice, hepatospleno-* Corresponding author. Tel.: +81 3 4582 2663; fax: +81 3 5285 1180.
E-mail address: ninoue@nih.go.jp (N. Inoue).
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asymptomatic at birth.3 In addition, CMV causes late-onset
neurological sequelae, such as sensorineural hearing loss (SNHL)
and developmental delay. In our congenital CMV screening
program, we analyzed 21 272 newborns and identiﬁed 66 cases
with congenital CMV infection (0.31%).4 Thirty percent of the cases
had typical clinical manifestations and/or showed abnormalities in
brain images at birth.
The potential risk factors for congenital CMV infection or
disease may include both viral and host factors. For example, viral
loads in the blood but not viral genotypes may inﬂuence clinical
outcomes.5–7 Host factors may include CMV-IgG avidity levels in
pregnant women, and cytotoxic T lymphocyte responses and
innate immunity in fetuses.8–10 There have been few studies on theses. Published by Elsevier Ltd. All rights reserved.
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tion.11 As fetuses and newborns have poor acquired immunity, the
innate immune system seems to have an important role.9,12
A growing accumulation of data has indicated that speciﬁc single
nucleotide polymorphisms (SNPs) in several Toll-like receptor (TLR)
genes have some association with an altered susceptibility to, or
clinical outcome of, infectious diseases.13 SNPs in the TLR genes are
associated with CMV disease in transplant recipients.14–16 It is
considered that CMV glycoproteins B and H stimulate the TLR-2
signal pathway, resulting in nuclear factor kappa B (NF-kB)
activation and the production of inﬂammatory cytokines.17,18
Although the direct involvement of TLR-4 in CMV recognition has
not been reported, dendritic cells stimulated by TLR ligands enhance
CMV-speciﬁc CD4+ and CD8+ T cell responses.19 TLR-9 is critical to
the process of CMV sensing to assure rapid antiviral responses.20,21
Here we examined whether SNPs in the TLR-2, TLR-4, and TLR-9
genes have any predictive values for congenital CMV infection and
for progression into CMV disease.
2. Methods
2.1. Human subjects
This study was approved by the ethics committee on human
subjects of each participating institute. We obtained informed
consent from the parents of enrolled participants. In this study, the
following 87 cases with congenital CMV infection (group B,
Figure 1) were analyzed. (1) Forty-eight cases (nine symptomatic
and 39 asymptomatic at birth, and four developed a late-onset
disease) identiﬁed in our prospective study: we previously
conducted a urine ﬁlter-based screening program for congenital
CMV infection and identiﬁed 66 cases from 21 272 babies born at
25 diverse study sites in six geographically separate areas of Japan,
without any selection bias.4 Blood specimens of 48 out of the 66
cases were used in this study based merely on their availability. (2)
Twenty-one cases who visited one of the study sites because of
developmental delay or SNHL and were diagnosed with congenital
CMV infection by retrospective assay using dried umbilical cord
specimens;22 15 of them were asymptomatic at birth. (3) Eighteen
cases who were suspected of congenital CMV infection before or at
birth and were conclusively diagnosed both by PCR detection and
by virus isolation of CMV in urine within 3 weeks after birth;5,23‘Asymptoma tic
cases at birth ’
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Figure 1. Grouping of the cases in the study cohort. To analyze the associations between 
into the groups as shown. The group codes are used in Tables 1 and 2. *Samples of rs38041
the text. (SNHL, sensorineural hearing loss.)three of them were asymptomatic at birth and two developed a
late-onset disease(s).
Instead of recruiting healthy infants as a control group, we used
the information from the database for the general Japanese
population as described below.
2.2. Clinical evaluation
Clinical information for all participants, including clinical man-
ifestations and results of audiological tests and brain imaging, were
extracted from their medical records. All infants diagnosed at birth
were followed up for 3.18  1.14 years (range 1.5–5.8 years). There was
no statistical difference in the follow-upperiods of groups E and F. Mental
and physical development was closely monitored at outpatient clinics.
Audiological tests were performed using auditory brainstem responses
and/or auditory steady-state responses, and brain imaging was done by
computed tomography and/or magnetic resonance imaging. All
participants underwent audiological tests and brain imaging.
We deﬁned ‘symptomatic cases at birth’ (group D) as any infant
with one or more clinically signiﬁcant manifestation at birth,
including microcephaly, chorioretinitis, SNHL, and a combination
of petechiae, hepatosplenomegaly, and jaundice. IUGR alone and
manifestations that are not pathognomonic for congenital CMV
infection, such as arrhythmia and ventricular septal defect (VSD),
were excluded from the category. Cases ‘symptomatic at birth and/or
developed permanent sequelae’ (group F) included (1) ‘symptomatic
cases at birth’ (group D), (2) any infants with CMV-associated major
abnormalities in their brain imaging at birth or later on, such as
intracranial calciﬁcations, ventriculomegaly, and white matter
disease, and/or (3) any infants with late-onset symptoms, including
SNHL, chorioretinitis, and developmental delay (group H). ‘Asymp-
tomatic cases’ (group E) were deﬁned as those who were not
categorized into group D in their follow-up periods. In addition to
cases without any manifestations, four cases with IUGR, one with
VSD, and two with arrhythmia were classiﬁed into group E.
2.3. Analysis of SNPs
Genomic DNA was extracted from peripheral blood mononuclear
cells or from dried umbilical cord specimens, using a commercial kit.
Integrity and quantity of the extracted DNA specimens were
evaluated by qPCR using the human albumin gene as a target.22Tota l enrolled
(Group B,  n = 87)
‘Sympto mat ic 
cases at birth ’
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target gene SNPs and congenital CMV infection or disease, participants were divided
00 in TLR-2 obtained from the database. Number of samples of other SNPs shown in
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two conditions: (1) the SNP is located in TLR-2, TLR-4, or TLR-9 and its
minor genotype frequency is >5% in the databases for the Japanese
general population to allow statistical analysis, and (2) association of
the SNP with the severity of viral disease or antiviral responses has
been reported previously. Only ﬁve SNPs in TLR-2, nine in TLR-4, and
four in TLR-9 have minor genotypes at frequencies of more than 5% in
the Japanese population. All of these 18 SNPs locate in the introns, in
the untranslated regions, or as synonymous alterations in open
reading frames (ORFs). We analyzed the following ﬁve SNPs:
rs3804100 and rs1898830 in TLR-2, rs11536889 in TLR-4, and
rs352139 and rs352140 in TLR-9, all of which have been reported to
be associated with the severity of viral disease or antiviral
responses.24–28 The frequencies of genotypes of each SNP in the
general Japanese population (group A, Figure 1, n = 83–86 for TLR-2
and TLR-9, n = 42 for TLR-4) were obtained from the National Center
for Biotechnology Information dbSNP and HapMap databases (http://
www.ncbi.nlm.nih.gov/projects/SNP/). Since individuals in the gen-
eral Japanese population in the database were recruited in Tokyo, to
where people move from most areas of Japan, the database can be
considered to reﬂect the general Japanese population.
Polymorphic sites in each DNA specimen were analyzed by
TaqMan allelic discrimination assay. Primers and probes listed in
the TaqMan SNP Genotyping Assays (Applied Biosystems) were
used for the analysis. Thermal cycling conditions were 2 min at
50 8C, 10 min at 95 8C, and 40 cycles each of 15 s at 92 8C and 1 min
at 60 8C. Accuracy of genotyping was conﬁrmed by inclusion ofTable 1
Associations between target gene SNPs and congenital CMV infection
Gene rs numbera (region) Genetic model Genotype
TLR-2 rs1898830 Codominant AA 
(Intron 1) AG 
GG 
Dominant AA 
AG + GG 
Recessive AA + AG 
GG 
rs3804100 Codominant TT 
(Exon 3) TC 
No amino acid change CC 
Dominant TT 
TC + CC 
Recessive TT + TC 
CC 
TLR-4 rs11536889 Codominant GG 
(30 UTR) GC 
CC 
Dominant GG 
GC + CC 
Recessive GG + GC 
CC 
TLR-9 rs352139 Codominant AA 
(Intron 1) AG 
GG 
Dominant AA 
AG + GG 
Recessive AA + AG 
GG 
rs352140 Codominant GG 
(Exon 2) GA 
No amino acid change AA 
Dominant GG 
GA + AA 
Recessive GG + GA 
AA 
SNP, single nucleotide polymorphism; CMV, cytomegalovirus; OR, odds ratio; CI, conﬁ
a Public database (dbSNP) reference number.
b Characteristics of each group are shown in Figure 1.
c p-Values were derived from the Chi-square test for 2  2 or 2  3 tables. A p-value
d p = 0.045 after Bonferroni multiple correction.control plasmids. The control plasmids were prepared as follows.
DNA fragments of 0.8–1.3 kb containing at least one of the targeted
SNP sites were ampliﬁed by PCR of genomic DNA and cloned into
pBluescriptSKII(+). The control plasmids containing minor alleles
were produced by oligonucleotide-based mutagenesis using a
commercial kit (Stratagene).
2.4. Statistical analyses
Hardy–Weinberg equilibrium, linkage disequilibrium analysis,
and haplotype analysis were performed using SNPStats software
(http://bioinfo.iconcologia.net/en/SNPStats_web). To analyze the
associations between target gene SNPs and congenital CMV
infection, we compared the genotypes of all cases in our cohort
(group B) to those of the general Japanese population in the
databases (group A). To analyze the associations of target gene SNPs
with congenital CMV disease, we compared the genotypes between
two groups in the following combinations: (1) group C vs. group D,
(2) group E vs. group F, and (3) group G vs. group H (Figure 1).
Genotype and allelic frequencies of all ﬁve SNPs were in Hardy–
Weinberg equilibrium among each group (data not shown).
Differences in the prevalence of genotyped polymorphisms between
two groups were estimated by odds ratios (ORs), 95% conﬁdence
intervals (95% CI), and p-values. ORs and 95% CI were calculated for
each group compared to the reference class (homozygous genotype
for the prevalent allele). p-Values were derived from the Chi-square
test for 2  2 or 2  3 tables. A p-value of <0.05 was considered to be General population (Ab) or congenital CMV infection (Bb)
A (%) B (%) OR (95% CI) p-Valuec
19.7 34.5 1 NS
62.8 47.1 0.43 (0.21–0.88)
17.4 18.4 0.60 (0.24–1.52)
19.7 34.5 1 0.030
80.2 65.5 0.47 (0.23–0.93)
82.6 81.6 1 NS
17.4 18.4 1.07 (0.49–2.32)
57.8 42.5 1 0.015d
41 47.1 1.56 (0.84–2.92)
1.2 10.3 11.7 (1.42–96.3)
57.8 42.5 1 0.046
42.2 57.5 1.85 (1.01–3.41)
98.8 89.7 1 0.011
1.2 10.3 9.46 (1.17–76.4)
57.1 51.7 1 NS
35.7 40.2 1.24 (0.57–2.72)
7.1 8 1.24 (0.29–5.25)
57.1 51.7 1 NS
42.9 48.3 1.24 (0.59–2.61)
92.9 92 1 NS
7.1 8 1.14 (0.28–4.64)
29.1 25.3 1 NS
43 54 1.44 (0.70–2.96)
27.9 20.7 0.85 (0.37–1.97)
29.1 25.3 1 NS
70.9 74.7 1.21 (0.62–2.37)
72.1 79.3 1 NS
27.9 20.7 0.67 (0.33–1.36)
29.1 25.3 1 NS
43 54 1.44 (0.70–2.96)
27.9 20.7 0.85 (0.37–1.97)
29.1 25.3 1 NS
70.9 74.7 1.21 (0.62–2.37)
72.1 79.3 1 NS
27.9 20.7 0.67 (0.33–1.36)
dence interval; NS, not signiﬁcant; UTR, untranslated region.
 of <0.05 was considered to be statistically signiﬁcant.
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multiple correction of p-values was applied.
3. Results
3.1. Associations between target gene SNPs and congenital CMV
infection
The homozygous CC genotype of SNP rs3804100 in TLR-2 was
identiﬁed in children with congenital CMV infection at aTable 2
Associations between target gene SNPs and congenital CMV disease
Gene rs numbera (region) Genetic model Genotype Asymptomatic (C
symptomatic (Db
C (%) D (%) 
TLR-2 rs1898830 Codominant AA 31.6 40.0 
(Intron 1) AG 47.4 46.7 
GG 21.1 13.3 
Dominant AA 31.6 40.0 
AG + GG 68.4 60.0 
Recessive AA + AG 79.0 86.7 
GG 21.1 13.3 
rs3804100 Codominant TT 36.8 53.3 
(Exon 3) TC 54.4 33.3 
No amino acid change CC 8.8 13.3 
Dominant TT 36.8 53.3 
TC + CC 63.2 46.7 
Recessive TT + TC 91.2 86.7 
CC 8.8 13.3 
TLR-4 rs11536889 Codominant GG 56.1 43.3 
(30 UTR) GC 35.1 50.0 
CC 8.8 6.7 
Dominant GG 56.1 43.3 
GC + CC 43.9 56.7 
Recessive GG + GC 91.2 93.3 
CC 8.8 6.7 
TLR-9 rs352139 Codominant AA 24.6 26.7 
(Intron 1) AG 54.4 53.3 
GG 21.1 20.0 
Dominant AA 24.6 26.7 
AG + GG 75.4 73.3 
Recessive AA + AG 79.0 80.0 
GG 21.1 20.0 
rs352140 Codominant GG 24.6 26.7 
(Exon 2) GA 54.4 53.3 
No amino acid change AA 21.1 20.0 
Dominant GG 24.6 26.7 
GA + AA 75.4 73.3 
Recessive GG + GA 79.0 80.0 
AA 21.1 20.0 
SNP, single nucleotide polymorphism; CMV, cytomegalovirus; OR, odds ratio; CI, conﬁ
Note: No p-values were signiﬁcant (data not shown).
a Public database (dbSNP) reference number.
b Characteristics of each group are shown in Figure 1.signiﬁcantly higher frequency in all considered genetic models
(OR 11.7, 95% CI 1.42–96.3, p = 0.015 in the codominant genetic
model) (Table 1). The heterozygous AG genotype at the
rs1898830 locus in TLR-2 tended to be identiﬁed in children
with congenital CMV infection at a lower frequency, in other
words the frequency of the homozygous AA genotype in children
with congenital CMV infection was higher than that in the
general population (OR 0.43, 95% CI 0.21–0.88 in the codomi-
nant genetic model; OR 0.47, 95% CI 0.23–0.93, p = 0.030 in the
dominant genetic model). The analysis of these two SNPs in theb) or
) at birth
Asymptomatic (Eb) or
symptomatic (Fb)
Without (Gb) or with (Hb)
late-onset symptoms
OR (95% CI) E (%) F (%) OR (95% CI) G (%) H (%) OR (95% CI)
Ref. 29.0 37.5 Ref. 33.3 28.6 Ref.
0.78
(0.29–2.06)
45.2 48.2 0.83
(0.30–2.28)
44.4 52.4 1.37
(0.40–4.77)
0.50
(0.13–1.92)
25.8 14.3 0.43
(0.12–1.50)
22.2 19.1 1.00
(0.21–4.71)
Ref. 29.0 37.5 Ref. 33.3 28.6 Ref.
0.69
(0.28–1.74)
71.0 62.5 0.68
(0.26–1.76)
66.7 71.4 1.25
(0.39–4.04)
Ref. 74.2 85.7 Ref. 77.8 81.0 Ref.
0.58
(0.17–1.97)
25.8 14.3 0.48
(0.16–1.44)
22.2 19.1 0.82
(0.21–3.15)
Ref. 41.9 42.9 Ref. 36.1 38.1 Ref.
0.42
(0.16–1.11)
51.6 44.6 0.85
(0.34–2.13)
55.6 52.4 0.89
(0.28–2.82)
1.05
(0.24–4.55)
6.5 12.5 1.90
(0.34–10.49)
8.3 9.5 1.08
(0.15–7.96)
Ref. 41.9 42.9 Ref. 36.1 38.1 Ref.
0.51
(0.21–1.25)
58.1 57.1 0.96
(0.40–2.34)
63.9 61.9 0.92
(0.30–2.79)
Ref. 93.5 87.5 Ref. 91.7 90.5 Ref.
1.60
(0.40–6.47)
6.5 12.5 2.07
(0.40–10.65)
8.3 9.5 1.16
(0.18–7.56)
Ref. 64.5 44.6 Ref. 62.9 42.9 Ref.
1.85
(0.73–4.68)
25.8 48.2 2.70
(1.01–7.22)
25.7 52.4 2.99
(0.92–9.66)
0.98
(0.17–5.73)
9.7 7.1 1.07
(0.21–5.33)
11.4 4.8 0.61
(0.06–6.25)
Ref. 64.5 44.6 Ref. 62.9 42.9 Ref.
1.67
(0.69–4.08)
35.5 55.4 2.25
(0.91–5.57)
37.1 57.1 2.26
(0.75–6.80)
Ref. 90.3 92.9 Ref. 88.6 95.2 Ref.
0.74
(0.14–4.08)
9.7 7.1 0.72
(0.15–3.44)
11.4 4.8 0.39
(0.04–3.72)
Ref. 19.4 28.6 Ref. 22.3 28.6 Ref.
0.90
(0.31–2.60)
61.3 50.0 0.55
(0.18–1.67)
61.6 42.9 0.55
(0.15–2.03)
0.88
(0.24–3.24)
19.4 21.4 0.75
(0.19–2.91)
16.7 28.6 1.33
(0.28–6.28)
Ref. 19.4 28.6 Ref. 22.2 28.6 Ref.
0.90
(0.33–2.46)
80.7 71.4 0.60
(0.21–1.74)
77.8 71.4 0.71
(0.21–2.44)
Ref. 80.7 78.6 Ref. 83.3 71.4 Ref.
0.94
(0.31–2.81)
19.4 21.4 1.14
(0.38–3.40)
16.7 28.6 2.00
(0.55–7.27)
Ref. 19.4 28.6 Ref. 23.1 27.8 Ref.
0.90
(0.31–2.60)
61.3 50.0 0.55
(0.18–1.67)
61.5 38.9 0.55
(0.15–2.03)
0.88
(0.24–3.24)
19.4 21.4 0.75
(0.19–2.91)
15.4 33.3 1.33
(0.28–6.28)
Ref. 19.4 28.6 Ref. 23.1 27.8 Ref.
0.90
(0.33–2.46)
80.7 71.4 0.60
(0.21–1.74)
76.9 72.2 0.71
(0.21–2.44)
Ref. 80.7 78.6 Ref. 84.6 66.7 Ref.
0.94
(0.31–2.81)
19.4 21.4 1.14
(0.38–3.40)
15.4 33.3 2.00
(0.55–7.27)
dence interval; UTR, untranslated region.
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in similar ﬁndings (data not shown).
There were no signiﬁcant differences in prevalence of
genotypes in SNPs rs11536889 in TLR-4 and rs352139 and
rs352140 in TLR-9 between groups A and B.
3.2. Absence of any association of SNPs with congenital CMV disease
As shown in Table 2, no statistically signiﬁcant associations
were observed for any SNPs between two groups in the following
combinations: (1) group C vs. group D, (2) group E vs. group F, and
(3) group G vs. group H. Inclusion of newborns with only IUGR or
with any single, non-pathognomonic manifestation into groups D
or F did not alter the overall results (data not shown). Further, no
haplotypes were associated with congenital CMV disease.
4. Discussion
In this study, we found that the frequencies of SNPs in TLR-2,
rs3804100 and rs1898830, in children with congenital CMV
infection differed from those in the general Japanese population
and that there were no signiﬁcant associations between SNPs in
the analyzed TLR genes and congenital CMV disease. Similar results
in the 48 cases identiﬁed in our screening program exclude a
possibility that selection bias due to enrichment with symptomatic
infants affected the association, since the screening population can
represent the Japanese general population.4 A potential drawback
of our study is that we could not analyze SNPs in the general
population completely matched with the congenital cases, since
the ethics committee restricted our genetic tests to congenital
cases. However, it is unlikely that there is a particular bias in the
genetic polymorphisms in the general Japanese population, since
the population in the database is comprised of individuals living in
Tokyo, the melting pot of Japan, and since the Japanese population
is believed to be homogeneous already. It would be important to
analyze more SNP loci in TLR-2 to conﬁrm our ﬁndings. An
additional limitation of our study includes the fact that the timing
and procedures for the neuroimaging examinations were not
uniform and thus we could not predict their effects on our analysis;
this might affect the statistical analysis comparing group E to
group F and group G to group H. Nevertheless, this limitation did
not affect our ﬁndings with regard to the difference between
groups A and B.
Maternal CMV infection does not always cause fetal infection;
for example, the transmission rate is expected to be around 40% in
mothers with primary infection,3 although the rates in mothers
with reinfection or with reactivation are unclear. Therefore, we
hypothesize that polymorphisms in TLR-2 could be the risk factors
for viral transmission at least from primary-infected mothers to
the fetus. Although we were also interested in the polymorphisms
in mothers, the material available for this purpose was insufﬁcient
to allow the design of a statistically meaningful study.
The frequency of the TT genotype of TLR-2 SNP rs3804100 in
responders to hepatitis B vaccine was found to be signiﬁcantly
higher than that in non-responders.24 The major alleles of SNP
rs3804100 in TLR-2 have been associated with a higher antibody
level in individuals with measles vaccine.25 SNP rs1898830
appeared to be involved in viral shedding and the lesion rate in
patients with genital herpes simplex virus type 2 infection.26
Hence, these two SNPs might be associated with TLR-2 gene
expression, which may affect the level of innate immunity against
viral infections in some way, in spite of the absence of any changes
in the amino acid sequences. There are many examples showing
the associations of polymorphisms located outside of ORFs. Several
studies have even reported that synonymous SNPs inﬂuence the
splicing process,29,30 post-transcriptional regulation,31 mRNAstability,32,33 translation efﬁciency, and protein folding.34 Howev-
er, it is difﬁcult to exclude a possibility that the TLR-2 SNPs are
simply genetic markers for other polymorphisms that link directly
to the risk factors for transmission. Further studies are required to
investigate the biological signiﬁcance of the synonymous SNPs for
which we identiﬁed the abovementioned differences.
A relationship between TLR-4 rs11536889 and protection from
hepatitis B virus recurrence after liver transplantation has been
reported.27 Also some TLR-4 SNPs might be related to CMV disease
in renal transplantation recipients.15 The haplotypes of TLR-9
rs352139 and rs352140 may inﬂuence mother-to-child transmis-
sion of HIV,28 and another SNP in TLR-9 was found to be highly
predictive of susceptibility to CMV infection in allogeneic stem cell
transplantation patients.16 However, we did not ﬁnd any signiﬁ-
cant associations between the SNPs in TLR-4 and TLR-9 and
congenital CMV infection or disease.
The identiﬁcation of high-risk groups might make treatment
with antiviral agents, such as ganciclovir,35 a more viable option in
the treatment of asymptomatic infants. Further studies on
polymorphisms in additional genes associated with the immune
systems may provide a means of identifying high-risk groups. The
analysis of polymorphisms not only in infected newborns but also
in their mothers may be important for the identiﬁcation of risk
factors.
In conclusion, TLR-2 polymorphisms may have some associa-
tion with congenital CMV infection, although the mechanism
underlying this effect remains to be clariﬁed.
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